

**MOL #112482**

# **Organic Cation Transporter 3 Facilitates Fetal Exposure to Metformin during Pregnancy**

Nora Lee, Mary F. Hebert, David J. Wagner, Thomas R. Easterling, C. Jason Liang, Kenneth Rice, and Joanne Wang

Departments of Pharmaceutics (N.L., D.J.W., J.W.), Pharmacy (M.F.H.), Obstetrics and Gynecology (M.F.H., T.R.E.), and Biostatistics (C.J.L. and K.R.); Obstetric-fetal Pharmacology Research Unit (N.L., M.F.H., T.R.E., J.W.), University of Washington, Seattle, WA 98195, United States

**MOL #112482**

**Running title:** OCT3 facilitates fetal metformin disposition in pregnancy

**Correspondence:**

Joanne Wang, Ph.D.  
University of Washington  
Department of Pharmaceutics  
H272 Health Sciences Building  
Seattle WA 98195-7610  
Phone: 206-221-6561  
Fax: 206-543-3204  
Email: [jowang@uw.edu](mailto:jowang@uw.edu)

**Word Counts**

**Text pages:** 27

**Tables:** 2

**Figures:** 6

**References:** 43

**Abstract:** 248 (max 250)

**Introduction:** 744 (max 750)

**Discussion:** 1,366 (max 1,500)

**Abbreviations:** AUC, area under the concentration-time curve;  $C_{\max}$ , peak plasma concentration; D-MEM, Dulbecco's modified Eagle medium; gd, gestational day; GDM, gestational diabetes mellitus; HEK, human embryonic kidney; MATE, multidrug and toxin extrusion protein; MPP<sup>+</sup>, 1-methyl-4-phenylpyridinium; NET, norepinephrine transporter; OCT, organic cation transporter; OCTN2, organic cation transporter novel type 2; PBS, phosphate buffered saline; PMAT, plasma membrane monoamine transporter; SERT, serotonin transporter

## MOL #112482

### ABSTRACT

Metformin, an oral anti-hyperglycemic, is increasingly being prescribed to pregnant women with gestational diabetes. Metformin is a hydrophilic cation and relies on organic cation transporters to move across cell membranes. We previously demonstrated that human and mouse placentas predominantly express organic cation transporter 3 (OCT3), but the impact of this transporter on maternal and fetal disposition of metformin is unknown. Using immunofluorescence colocalization studies in term human placenta, we showed that OCT3 is localized to the basal (fetal-facing) membrane of syncytiotrophoblast cells with no expression on the apical (maternal-facing) membrane. OCT3 positive staining was also observed in fetal capillaries. To determine the *in vivo* role of OCT3 in maternal and fetal disposition of metformin, we determined metformin maternal pharmacokinetics and overall fetal exposure in wildtype and *Oct3*-null pregnant mice. After oral dosing of [ $^{14}\text{C}$ ]metformin at gestational day 19, the systemic drug exposure ( $\text{AUC}_{0-\infty}$ ) in maternal plasma was slightly reduced by ~ 16% in the *Oct3*<sup>-/-</sup> pregnant mice. In contrast, overall fetal  $\text{AUC}_{0-\infty}$  was reduced by 47% in the *Oct3*<sup>-/-</sup> pregnant mice. Consistent with our previous findings in non-pregnant mice, metformin tissue distribution was respectively reduced by 70% and 52% in the salivary glands and heart in *Oct3*<sup>-/-</sup> pregnant mice. Our *in vivo* data in mice clearly demonstrated a significant role of Oct3 in facilitating metformin fetal distribution and exposure during pregnancy. Modulation of placental OCT3 expression or activity by gestational age, genetic polymorphism, or pharmacological inhibitors may alter fetal exposure to metformin or other drugs transported by OCT3.

## **INTRODUCTION**

Gestational diabetes mellitus (GDM) is a complication characterized by insulin resistance and glucose intolerance during pregnancy. GDM affects about 5-13% of pregnancies in the US; uncontrolled GDM can lead to serious adverse outcomes for the mother and fetus, such as difficult labor, hypertensive disorders, and preeclampsia as well as neonatal hypoglycemia, respiratory distress syndrome, and macrosomia (Farrell, 2003; Simmons, 2011; Ryu *et al.*, 2014). Historically, insulin has been the mainstay drug for the treatment of GDM. In recent years, oral hypoglycemic agents are increasingly being used in the management of GDM due to the ease of administration, lower cost, and better patient adherence than insulin (Ryu *et al.*, 2014).

Metformin, a frontline drug for type 2 diabetes outside pregnancy, is increasingly being used in the treatment of GDM. Metformin acts as an insulin sensitizer and lowers blood glucose levels by suppressing hepatic gluconeogenesis, reducing intestinal glucose absorption, and stimulating glucose uptake in skeletal muscle and adipose tissues (Hundal and Inzucchi, 2003; Gong *et al.*, 2012). Metformin is predominantly eliminated by the kidney with negligible hepatic elimination (Scheen, 1996; N Kimura *et al.*, 2005; Tanihara *et al.*, 2007). Membrane transporters play a critical role in metformin pharmacokinetics and pharmacodynamics because it is hydrophilic and positively charged at physiological pH. Metformin is a substrate of multiple transporters, including the organic cation transporters 1-3 (OCT1–3), multidrug and toxin extrusion protein 1 and 2-K (MATE1, MATE2-K), and the plasma membrane monoamine transporter (PMAT) (Zhou *et al.*, 2007; Gong *et al.*, 2012). In humans, the liver-specific OCT1 (SLC22A1) mediates metformin uptake into the hepatocyte, a major site of metformin action (Hundal and Inzucchi, 2003; Gong *et al.*, 2012; Wagner *et al.*, 2016). The kidney-specific OCT2 (SLC22A2) works in concert with MATE1/2-K to mediate active secretion of metformin in renal

## MOL #112482

tubular cells (Naoko Kimura *et al.*, 2005; Masuda *et al.*, 2006; Tanihara *et al.*, 2007; Morrissey *et al.*, 2013). The third member of the human OCT family, OCT3 (SLC22A3), is broadly distributed in many tissues, including the placenta, salivary glands, heart, brain, and intestine (Wu *et al.*, 2000) (Lee *et al.*, 2014). We previously showed that OCT3/Oct3 is the primary organic cation transporter expressed in salivary gland epithelial cells and is responsible for metformin accumulation and secretion in salivary glands (Lee *et al.*, 2014). Recently, we and others observed a reduced metformin oral bioavailability in non-pregnant *Oct3*<sup>-/-</sup> mice, suggesting that this transporter may also play a role in intestinal absorption of metformin (Chen *et al.*, 2015; Shirasaka *et al.*, 2016).

The use of metformin in pregnant women with GDM has brought attention to its passage across the placenta barrier (Charles *et al.*, 2006; Wensel, 2009; Eyal *et al.*, 2010). Despite a very low passive membrane permeability, metformin readily crosses the placenta barrier (Vanky *et al.*, 2005; Charles *et al.*, 2006; Eyal *et al.*, 2010). Clinical studies performed by us and others have reported that umbilical cord serum concentrations of metformin at the time of delivery were comparable to or even exceeded maternal concentrations, suggesting that metformin is actively transported from maternal circulation to fetal blood (Vanky *et al.*, 2005; Charles *et al.*, 2006; Eyal *et al.*, 2010). Several in vitro and ex vivo studies also indicated the involvement of organic cation transporters in transplacental transport of metformin (Zwart *et al.*, 2001; Kovo, Haroutiunian, *et al.*, 2008; Kovo, Kogman, *et al.*, 2008). Among the known organic cation transporters, OCT3/Oct3 is the major isoform expressed in the placenta (Wu *et al.*, 2000; Verhaagh *et al.*, 2001; Zwart *et al.*, 2001; Lee *et al.*, 2013). Using uptake studies and western blot analysis in membrane vesicles prepared from human term placenta, Sata *et al.* first demonstrated that OCT3 is expressed in basal but not microvillous membrane vesicles (Sata *et*

## MOL #112482

*al.*, 2005). Using quantitative PCR and targeted proteomics, we previously demonstrated that human and mouse placentas predominantly express OCT3/Oct3 mRNA and protein with minimal expression of other metformin transporters including OCT1/2, MATE1/2, and PMAT (Lee *et al.*, 2013). Expression of OCT3/Oct3 in human and mouse placentas is influenced by gestational age with higher expression in late pregnancy (Lee *et al.*, 2013). Based on these observations, we hypothesized that OCT3/Oct3 is involved in placental metformin transport and influences fetal exposure to metformin. The goal of this study is to determine the subcellular localization of OCT3 in human placenta by immunofluorescence colocalization and evaluate the *in vivo* significance of Oct3 in fetal metformin exposure using a pregnant mouse model with deletion of the *Oct3* (*Slc22a3*) gene.

## MATERIALS AND METHODS

**Animals.** The *Oct3* (*Slc22a3*) null mice of the FVB inbred strain were originally developed by Dr. Denise Barlow (Zwart *et al.*, 2001) and maintained by Dr. Alfred Schinkel (Netherlands Cancer Institute). After re-derivation at Charles River Laboratories (Zhu *et al.*, 2010), breeding pairs of the wild type (*Oct3*<sup>+/+</sup>) and knockout (*Oct3*<sup>-/-</sup>) FVB mice were generously provided to us by Dr. John Markowitz at the University of Florida with approval from Dr. Schinkel. These mice were housed in the specific pathogen-free facility at the University of Washington. Mice were maintained on a 12/12-h automatically timed light/dark cycle under a standard diet. The animal studies were approved by the Institutional Animal Care and Use Committee of the University of Washington.

**Uptake Experiments.** Human OCT3 (hOCT3)-expressing HEK cells (Flp-In-293, Invitrogen, ) were previously generated (Duan and Wang, 2010). Cells stably transfected with pcDNA5/FRT

## MOL #112482

vector were used as a control. Cells were maintained in D-MEM containing 10% fetal bovine serum, 1% L-Glutamine, 1% penicillin/streptomycin, and hygromycin B (150 µg/ml) at 37°C in 5% CO<sub>2</sub> and 95% humidity. Metformin uptake and kinetic parameters were determined by radiotracer uptake assay as described previously (Lee *et al.*, 2014; Wagner *et al.*, 2017). Uptake experiments were performed in triplicate and repeated three times. Data are presented as mean ± S.D.

**Localization of OCT3 in Human Placenta.** Human term placentas from healthy uncomplicated pregnancies were obtained at the Labor and Delivery Unit at the University of Washington (Lee *et al.*, 2013). Upon collection, placentas were immediately snap frozen and stored at -80°C until use. Frozen sections were prepared by Pathology Research Services at the University of Washington, and immunofluorescence staining was carried out using a procedure developed in our laboratory (Lee *et al.*, 2014). Briefly, frozen human term placenta sections were fixed in ice cold acetone for 5 min, immersed in PBS for 5 min, and then blocked in goat serum in PBS for 45 min at room temperature. The sections were then incubated overnight at 4 °C with a polyclonal rabbit anti-OCT3 (1:125 dilution; Genway, San Diego, CA), co-labeled with either anti-human CD31-PECAM1 (1:50 dilution; R&D Systems, Minneapolis, MN), anti-human laminin (1:1000 dilution; Sigma-Aldrich, St. Louis, MO), or anti-human CD71 (transferrin receptor) (1:200 dilution; Abbiotec, San Diego, CA). After primary antibody incubation, the sections were washed with PBS, and fluorescent tag-labeled secondary antibodies (Alexa 488 and Alexa 568, 1:500 dilution) were applied for 1 hr at room temperature. For nonspecific control, placenta tissue sections were incubated with blank serum, followed by secondary antibody incubation under the same conditions. After washing, ProLong Gold

## MOL #112482

antifade medium with DAPI was mounted on the slides and cover-slipped. Fluorescent images were obtained with a Zeiss Axiovert 200 fluorescence microscope.

**Transporter Expression Analysis in *Oct3*<sup>+/+</sup> and *Oct3*<sup>-/-</sup> Placentas.** To determine if there were compensatory changes in the expression of other organic cation and related transporters in placentas of *Oct3*<sup>-/-</sup> mice, pregnant *Oct3*<sup>+/+</sup> and *Oct3*<sup>-/-</sup> mice at gd 19 were sacrificed using CO<sub>2</sub>. The placentas were immediately collected, flash-frozen in liquid N<sub>2</sub>, and stored at -80°C until use. Total RNA was extracted using Qiagen Mini RNeasy Kit (Valencia, CA) and reverse transcribed to first-strand cDNA using Invitrogen Superscript III reverse transcriptase according to the manufacturers' instruction. Taqman real-time PCR assays were carried out according to the manufacturer's protocols on an Applied Biosystems 7900HT fast real-time PCR system (Foster City, CA) as described previously (Duan and Wang, 2010; Lee *et al.*, 2013).

**In vivo Pharmacokinetics Studies.** All in vivo studies were carried out in pregnant mice at gestational day (gd) 19 (term in mice is approximately 20-21days), as we previously showed that the expression of Oct3 in the mouse placenta peaks around gd19 (Lee *et al.*, 2013). To obtain pregnant *Oct3*<sup>+/+</sup> or *Oct3*<sup>-/-</sup> mice at gd 19, male and female mice (8–10 weeks old) of each genotype were mated. Gestational age was determined based on the estimated time of insemination, and the day that a vaginal plug was observed was assigned as gestational day 1. Progression of pregnancy was regularly monitored by visual inspection and by measuring the increase in body weight. At gd 19, mice were administered 15 mg/kg metformin containing 0.2 mCi/kg [<sup>14</sup>C]metformin (Moravek Biochemicals, Inc.; Carlsbad, CA) by oral gavage. At various time points (15, 30, 45, 60, 120, 180, 240, and 480 min), mice (*n* = 3-5 mice at each time point) were sacrificed by CO<sub>2</sub> inhalation followed by cardiac puncture. Blood was collected using a



## MOL #112482

heparin-coated syringe. Plasma was separated by centrifugation at  $5000 \times g$  and stored at  $-20^{\circ}\text{C}$  until analysis. Fetus and various maternal tissues were collected at each time point, snap-frozen in liquid  $\text{N}_2$ , and stored at  $-80^{\circ}\text{C}$  until use. Metformin concentrations in maternal plasma, tissue and fetus homogenates were determined by scintillation counting using the method described by us previously (Lee *et al.*, 2014). Metformin concentration was expressed as nanograms/g for tissues and nanograms/ml for plasma.

**Pharmacokinetic Data Analysis.** A population-based bootstrap method (Mager and Göller, 1998; Lee *et al.*, 2014) was used to calculate the mean and confidence intervals of area under the concentration-time curves (AUCs) because metformin concentrations in plasma and tissue were sampled in different animals at each time point (one-point sampling). The following equations were used to obtain maternal plasma AUC, oral clearance (CL/F), terminal half-life ( $t_{1/2,\beta}$ ), and volume of distribution at terminal phase ( $V_{\beta}$ )

$$\text{AUC}_{0-t} = \int_0^t C(t) dt$$

$$\text{AUC}_{0-\infty} = \text{AUC}_{0-t} + \frac{C(T)}{\beta}$$

$$\frac{\text{CL}}{F} = \frac{\text{Dose}}{\text{AUC}_{0-\infty}}$$

$$t_{1/2,\beta} = \frac{\ln 2}{\beta}$$

$$V_{\beta} = \frac{\text{CL}}{F \cdot \beta}$$

## MOL #112482

The terminal slope ( $\beta$ ) was calculated by performing a linear regression of log concentrations at the last three to five time points that provided the best correlation ( $R^2$ ). The 95% confidence intervals for pharmacokinetic parameters were generated using a bootstrap method as described previously (Lee *et al.*, 2014). Briefly, plasma or tissue concentrations were resampled with random replacement of individual animals using the R program to create pseudo concentration-time profiles. For each profile, the pharmacokinetic parameters were calculated using the equations defined above. The 95% confidence intervals for each parameter were calculated by taking the 2.5 and 97.5% quartiles. Peak plasma concentration ( $C_{\max}$ ) was estimated by visual inspection of the plasma concentration-time curve averaged from all animals.

**Statistical Analysis.** Data from in vitro studies were analyzed for statistical significance using unpaired Student's *t* test. For pharmacokinetic data, 95% confidence intervals around the estimate for each pharmacokinetic parameter were determined using the non-parametric bootstrap method (Efron and Tibshirani, 1994). Two-sided *P* values were calculated using permutation tests as described previously (Westfall and Young, 1993; Lee *et al.*, 2014). A *P* value <0.05 was considered statistically significant.

## MOL #112482

### RESULTS

**Transport of Metformin by hOCT3 Stably Expressed in HEK 293 Cells.** Using HEK293 cells stably expressing hOCT3, we determined the time- and concentration-dependent metformin uptake by hOCT3 (Supplemental Figure 1). hOCT3-mediated metformin uptake was saturable with a  $K_m$  value of  $1.16 \pm 0.19$  mM and a  $V_{max}$  value of  $3.12 \pm 0.17$  nmol/min/mg total protein. The  $K_m$  value is similar to that previously obtained by Chen et al. for hOCT3 (Chen *et al.*, 2010) and is also comparable to the  $K_m$  values reported for mouse Oct3 (Lee *et al.*, 2014; Chen *et al.*, 2015).

**Expression and Membrane Localization of OCT3 in Human Placenta.** To determine the membrane localization and cell type-specific expression of OCT3 in human placenta, we performed immunofluorescence localization studies in healthy human term placentas. The specificity of the OCT3 polyclonal antibody was validated in our previous studies (Lee *et al.*, 2014). As shown in Figure 1, positive staining of OCT3 was observed in syncytiotrophoblasts as well as in fetal capillaries. Double immunostaining revealed significant co-staining with laminin, a strong marker of the basement membrane, as well as CD31-PECAM1, a marker of the fetal vascular endothelium. In contrast, transferrin receptor, a marker of the microvillous (i.e. apical) membrane, showed no overlap with OCT3. No marked fluorescence was observed in slides treated with secondary antibodies (data not shown). These data demonstrated that OCT3 is localized to the basal (fetal-facing) membrane of the placental trophoblast cells and is also present in fetal endothelial cells.

**Metformin Pharmacokinetic Studies in Pregnant *Oct3*<sup>+/+</sup> and *Oct3*<sup>-/-</sup> Mice.** To determine the in vivo significance of OCT3 in maternal and fetal metformin disposition, we performed

## MOL #112482

metformin pharmacokinetic studies in pregnant *Oct3<sup>+/+</sup>* and *Oct3<sup>-/-</sup>* mice at gestational day 19. Prior to the pharmacokinetic studies, the mRNA expression of organic cation and related transporters was measured by quantitative RT-PCR in the placentas of *Oct3<sup>+/+</sup>* and *Oct3<sup>-/-</sup>* mice. The data revealed no significant compensatory change in mRNA expression of these transporters (Figure 2). At gd 19, *Oct3<sup>+/+</sup>* or *Oct3<sup>-/-</sup>* pregnant mice were given by oral gavage a dose of 15 mg/kg metformin containing 0.2 mCi/kg [<sup>14</sup>C]metformin. Mice were sacrificed at each time point (15 - 480 min) with metformin concentrations in maternal plasma, fetus and tissue homogenates measured. The maternal plasma concentration-time profiles and pharmacokinetic parameters in *Oct3<sup>+/+</sup>* and *Oct3<sup>-/-</sup>* pregnant mice are shown in Figure 3 and Table 1. After drug administration, peak metformin concentrations were achieved around 30 min and the drug was mostly eliminated from the maternal circulation at 480 min in both *Oct3<sup>+/+</sup>* and *Oct3<sup>-/-</sup>* pregnant mice (Figure 3). Compared to the wt pregnant mice, *Oct3<sup>-/-</sup>* pregnant mice showed a narrower peak in the plasma concentration-time curve with a slightly lower (~ 16%) AUC (Table 1). Other pharmacokinetic parameters were not statistically different between the *Oct3<sup>+/+</sup>* and *Oct3<sup>-/-</sup>* pregnant mice (Table 1).

**Impact of *Oct3* Deletion on Fetal Disposition of Metformin.** At each time point of the pharmacokinetics study (Figure 3), fetuses were collected and metformin concentrations in fetal tissue homogenate were determined (Figure 4). After maternal drug administration, metformin fetal concentration increased progressively and peaked at ~120 min in *Oct3<sup>+/+</sup>* mice and ~60 min in *Oct3<sup>-/-</sup>* mice (Figure 4). Compared to fetuses in wt pregnant mice, a trend of lower fetal concentrations of metformin was observed in the *Oct3<sup>-/-</sup>* pregnant mice throughout the time course. At 120 and 180 min, fetal drug concentrations in the *Oct3<sup>-/-</sup>* pregnant mice were only ~50% of those in the wt mice. The calculated fetal AUC<sub>0-480 min</sub> and extrapolated AUC<sub>0-∞</sub> in the

## MOL #112482

*Oct3*<sup>-/-</sup> pregnant mice were reduced by 39% and 47%, respectively (Table 2). When the fetal-to-maternal plasma AUC ratio was calculated, the *Oct3*<sup>-/-</sup> pregnant mice showed approximately ~30-40% reduction (Table 2). These data clearly demonstrated that fetal metformin exposure is significantly reduced in the *Oct3*<sup>-/-</sup> pregnant mice.

**Impact of *Oct3* Deletion on Metformin Tissue Distribution in Pregnant Mice.** In non-pregnant male and female mice, we previously observed a substantial reduction in metformin tissue exposure in salivary glands and heart in the *Oct3*<sup>-/-</sup> mice, consistent with a high and predominant expression of Oct3 in these tissues in wt mice (Lee *et al.*, 2014). When tissue metformin concentrations were measured in *Oct3*<sup>+/+</sup> and *Oct3*<sup>-/-</sup> pregnant mice, the knockout mice showed a 70% and 52% reduction in metformin AUC<sub>0-480 min</sub> in salivary glands and heart, respectively (Figure 5). A small reduction was also observed in the kidney and placenta while no significant difference was observed in skeletal muscle and liver (Figure 5).

## DISCUSSION

Metformin is increasingly being prescribed to pregnant women with GDM. Metformin readily crosses the placental barrier but the underlying transport mechanism is unclear. In this study, we determined the subcellular localization of OCT3 in human placenta and investigated the *in vivo* role of Oct3 in fetal and maternal metformin disposition using a pregnant mouse model with *Oct3* gene deletion. Our data demonstrated that OCT3 is localized to the basal membrane of the placental barrier and facilitates maternal-to-fetal transport of metformin. Our data revealed a significant impact of Oct3 on fetal and maternal metformin tissue distribution and pharmacokinetics.

## MOL #112482

The placenta is an important barrier tissue that mediates the exchange of nutrients, metabolites, and drugs between maternal and fetal circulation. This function is achieved by a multitude of transport proteins differentially expressed in the apical (maternal-facing) or basal (fetal-facing) membrane to mediate substrate transfer across the placenta (Ganapathy *et al.*, 2000; Vähäkangas and Myllynen, 2009). Using functional studies and western blot analysis in membrane vesicles prepared from human placenta, Sata *et al.* previously showed that OCT3 is expressed at basal membrane of human placenta trophoblasts (Sata *et al.*, 2005). Using immunofluorescence colocalization studies, we confirmed that OCT3 is localized to the basal, but not apical, membrane (Figure 1). Our study further revealed that OCT3 is also present in fetal endothelial cells (Figure 1). While the physiological function of OCT3 in the placenta is still unclear, the transporter is generally believed to serve as a clearing mechanism for bioactive amines (Ganapathy *et al.*, 2000; Ganapathy and Prasad, 2005; Duan and Wang, 2010). In the fetus, circulating catecholamine levels are kept low for the maintenance of cardiovascular homeostasis (Bzorkie *et al.*, 1997). The presence OCT3 in fetal capillaries may help to clear endogenous amines from the fetal circulation.

Because OCT3 is a bi-directional transporter driven by membrane potential, it can transport a substrate into or out of cells depending on the electrochemical gradient of the substrate. The basal localization of OCT3 suggests that the transporter may couple with an active uptake transporter at the apical membrane to mediate maternal-to-fetal transport. This would facilitate drug transfer into the fetus and increase fetal drug exposure. Alternatively, OCT3 may couple with an efflux transporter at the apical membrane to mediate fetal-to-maternal transport. This would promote drug clearance from the fetal compartment and decrease drug exposure in the fetus. To determine the actual role of Oct3 in placental transport of metformin in

## MOL #112482

vivo, we performed pharmacokinetic studies in *Oct3<sup>+/+</sup>* and *Oct3<sup>-/-</sup>* pregnant mice at gd 19. We chose to perform studies at gd 19 because we previously showed that OCT3/Oct3 expression in human and mouse placentas is gestational age-dependent and reaches highest in late pregnancy (Lee *et al.*, 2014). Metformin is highly water soluble and not bound to plasma proteins (Tucker *et al.*, 1981; Graham *et al.*, 2011). The clinical dosage of metformin can range from 500 to 3000 mg/day. After a single oral dose, the peak plasma concentrations range from 1.0 to 1.6 mg/L after a 0.5 g dose, increasing to about 3 mg/L after a 1.5 g dose (Tucker *et al.*, 1981; Graham *et al.*, 2011). At the oral dose (15 mg/kg) used in our study, the observed  $C_{\max}$  in the maternal plasma in wt and knockout mice are 3.3 and 4.2 mg/L (Table 1), which are within the range of clinically observed metformin concentrations. The observed metformin  $C_{\max}$  in wt and knockout mice (26 and 32  $\mu$ M, respectively) are far below its  $K_m$  towards the OCT3/Oct3 transporter (Supplemental Figure 1) (Chen *et al.*, 2010, 2015; Lee *et al.*, 2014), suggesting that our pharmacokinetic studies were conducted at plasma concentrations not saturating the Oct3 transporter.

Compared to wt pregnant mice, *Oct3<sup>-/-</sup>* pregnant mice showed a narrower peak in the maternal plasma concentration-time profile (Figure 3), similar to that observed in non-pregnant *Oct3<sup>-/-</sup>* mice (Lee *et al.*, 2014). This is likely due to a reduction in Oct3-mediated metformin distribution into peripheral tissues such as the salivary glands, heart, and the fetal compartment. The maternal plasma AUC of metformin in the *Oct3<sup>-/-</sup>* pregnant mice is only slightly reduced, which may be due to a small reduction in oral absorption as previously observed in non-pregnant *Oct3<sup>-/-</sup>* mice (Chen *et al.*, 2015; Shirasaka *et al.*, 2016). In contrast, fetal AUC was substantially reduced in the *Oct3<sup>-/-</sup>* pregnant mice (Figure 4, Table 2). This reduction cannot be accounted for by the small reduction in the maternal AUC in knockout mice as there was still a significant

## MOL #112482

reduction in fetal drug exposure after normalizing to maternal plasma AUC (Table 2). Thus, our in vivo data in mice clearly demonstrated a significant role of Oct3 in facilitating metformin fetal distribution and exposure during pregnancy.

Several groups have investigated the role of OCT3 in drug transport at the placenta barrier (Ganapathy *et al.*, 2000; Zwart *et al.*, 2001; Sata *et al.*, 2005; Vähäkangas and Myllynen, 2009; Ahmadimoghaddam *et al.*, 2012). In their original characterization of the *Oct3* knockout mice, Zwart *et al.* showed that when MPP<sup>+</sup>, an experimental substrate of OCT3/Oct3, was administered into maternal circulation during pregnancy, MPP<sup>+</sup> concentration measured at a single time point was significantly decreased in the embryos of the *Oct3*<sup>-/-</sup> genotype (Zwart *et al.*, 2001). This study suggested that Oct3 facilitates MPP<sup>+</sup> transport from maternal blood into the fetus. However, based on Mate1 expression and ex vivo studies in a perfused rat placenta model, Ahmadimoghaddam *et al.* proposed a protective role of Oct3 at the placenta barrier. They suggested that analogous to renal organic cation secretion mediated by OCT2 and MATE1, Oct3 at the basal membrane transports metformin from fetal blood to the syncytiotrophoblast, which is then effluxed into the maternal blood by Mate1 at the apical membrane (Ahmadimoghaddam *et al.*, 2012; Ahmadimoghaddam and Staud, 2013). Our data from comprehensive pharmacokinetic analyses in pregnant *Oct3*<sup>-/-</sup> mice are consistent with the initial finding by Zwart *et al.* and clearly support a role of Oct3 in facilitating maternal-to-fetal drug transport in vivo. Moreover, unlike the rat placenta, human and mouse placentas minimally express MATE1/Mate1 (Otsuka *et al.*, 2005; Lee *et al.*, 2013), indicating that an OCT3/MATE1-mediated fetal-to-maternal elimination pathway may not exist in these species.

Our in vivo studies suggest that metformin in the maternal circulation is transported into the syncytiotrophoblast cells by an apical transporter and is then effluxed into the fetal side by



## MOL #112482

basal Oct3. According to this model, there ought to be an apical transporter to initiate metformin uptake from the maternal blood. The molecular identity of this transporter is currently unclear. Previously, Ganapathy and Prasad had hypothesized that organic cations (e.g. MPP<sup>+</sup>) may be transported into placenta cells by the serotonin transporter (SERT) and/or norepinephrine transporter (NET), which are Na<sup>+</sup> and Cl<sup>-</sup> dependent secondary active transporters known to be expressed at the apical membrane of placenta (Ganapathy and Prasad, 2005). Metformin has been reported to be a transportable substrate of SERT (Han *et al.*, 2015). In addition, the organic cation/carnitine transporter OCTN2 is expressed at the apical membrane and may mediate organic cation uptake into the syncytiotrophoblast cells (Ganapathy and Prasad, 2005; Grube *et al.*, 2005). While more studies are necessary to validate the transporter(s) responsible for metformin uptake at the apical membrane, we propose a molecular model for organic cation transport at the placenta barrier based on our current study and available information in the literature (Figure 6).

In conclusion, our study demonstrated that OCT3 is localized to the basal membrane of human placenta trophoblast cells and fetal exposure to metformin is significantly reduced in the *Oct3*<sup>-/-</sup> pregnant mice. Our data support a role of Oct3 in facilitating maternal-to-fetal drug transport at the placenta barrier, leading to enhanced fetal exposure to metformin. To our knowledge, this is the first complete pharmacokinetics study that clearly established Oct3 as an important determinant of fetal exposure to metformin in vivo. It is reasonable to speculate a similar role of OCT3 on fetal exposure to metformin during human pregnancy because human and mouse placentas share a similar expression pattern of the OCT/Oct transporters (Lee *et al.*, 2014). If so, modulation of OCT3 activity by gestational age, genetic polymorphism, or

**MOL #112482**

pharmacological inhibitors may have clinical consequence on fetal exposure to metformin or other drugs transported by OCT3.

## MOL #112482

### ACKNOWLEDGMENTS

We are thankful to Drs. John Markowitz and Haojie Zhu (University of Florida) for providing breeding pairs of *Oct3*<sup>+/+</sup> and *Oct3*<sup>-/-</sup> mice for our study.

### AUTHORSHIP CONTRIBUTIONS

*Participated in research design:* Wang, Lee, Hebert

*Conducted experiments:* Lee

*Performed data analysis:* Lee, Wang, Liang, Rice, Wagner

*Contributed new reagents or analytical tools:* Easterling, Liang, Rice

*Wrote or contributed to writing of the manuscript:* Wang, Lee, Wagner, Hebert

## REFERENCES

- Ahmadimoghaddam D, Hofman J, Zemankova L, Nachtigal P, Dolezelova E, Cervený L, Ceckova M, Micuda S, and Staud F (2012) Synchronized activity of organic cation transporter 3 (Oct3/Slc22a3) and multidrug and toxin extrusion 1 (Mate1/Slc47a1) transporter in transplacental passage of MPP<sup>+</sup> in rat. *Toxicol Sci* **128**:471–481.
- Ahmadimoghaddam D, and Staud F (2013) Transfer of metformin across the rat placenta is mediated by organic cation transporter 3 (OCT3/SLC22A3) and multidrug and toxin extrusion 1 (MATE1/SLC47A1) protein. *Reprod Toxicol* **39**:17–22, Elsevier Inc.
- Bzoskie L, Blount L, Kashiwai K, Humme J, and Padbury JF (1997) The contribution of transporter-dependent uptake to fetal catecholamine clearance. *Biol Neonate* **71**:102–10.
- Charles B, Norris R, Xiao X, and Hague W (2006) Population pharmacokinetics of metformin in late pregnancy. *Ther Drug Monit* **28**:67–72.
- Chen EC, Liang X, Yee SW, Geier EG, Stocker SL, Chen L, and Giacomini KM (2015) Targeted Disruption of Organic Cation Transporter 3 Attenuates the Pharmacologic Response to Metformin. *Mol Pharmacol* **88**:75–83.
- Chen L, Pawlikowski B, Schlessinger A, More SS, Stryke D, Johns SJ, Portman MA, Chen E, Ferrin TE, Sali A, and Giacomini KM (2010) Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action of metformin. *Pharmacogenet Genomics* **20**:687–699.
- Duan H, and Wang J (2010) Selective transport of monoamine neurotransmitters by human plasma membrane monoamine transporter and organic cation transporter 3. *J Pharmacol*

**MOL #112482**

*Exp Ther* **335**:743–753.

Efron B, and Tibshirani RJ (1994) *An introduction to the bootstrap*, CRC press.

Eyal S, Easterling TR, Carr D, Umans JG, Miodovnik M, Hankins GD V, Clark SM, Risler L, Wang J, Kelly EJ, Shen DD, and Hebert MF (2010) Pharmacokinetics of metformin during pregnancy. *Drug Metab Dispos* **38**:833–840.

Farrell M (2003) Improving the care of women with gestational diabetes. *MCN Am J Matern Child Nurs* **28**:301–5.

Ganapathy V, and Prasad PD (2005) Role of transporters in placental transfer of drugs. *Toxicol Appl Pharmacol* **207**:381–387.

Ganapathy V, Prasad PD, Ganapathy ME, and Leibach FH (2000) Placental transporters relevant to drug distribution across the maternal-fetal interface. *J Pharmacol Exp Ther* **294**:413–20.

Gong L, Goswami S, Giacomini KM, Altman RB, and Klein TE (2012) Metformin pathways: pharmacokinetics and pharmacodynamics. *Pharmacogenet Genomics* **22**:820–827.

Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong JK, Furlong TJ, Greenfield JR, Greenup LC, Kirkpatrick CM, Ray JE, Timmins P, and Williams KM (2011) Clinical pharmacokinetics of metformin. *Clin Pharmacokinet* **50**:81–98.

Grube M, Meyer Zu Schwabedissen H, Draber K, Präger D, Möritz K-U, Linnemann K, Fusch C, Jedlitschky G, and Kroemer HK (2005) Expression, localization, and function of the carnitine transporter octn2 (slc22a5) in human placenta. *Drug Metab Dispos* **33**:31–7.

Han TK, Proctor WR, Costales CL, Cai H, Everett RS, and Thakker DR (2015) Four cation-

# MOL #112482

selective transporters contribute to apical uptake and accumulation of metformin in Caco-2 cell monolayers. *J Pharmacol Exp Ther* **352**:519–528.

Hundal RS, and Inzucchi SE (2003) Metformin: New understandings, new uses. *Drugs* **63**:1879–1894.

Kimura N, Masuda S, Tanihara Y, Ueo H, Okuda M, Katsura T, and Inui K-I (2005) Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. *Drug Metab Pharmacokinet* **20**:379–386.

Kimura N, Okuda M, and Inui K (2005) Metformin transport by renal basolateral organic cation transporter hOCT2. *Pharm Res* **22**:255–259.

Kovo M, Haroutiunian S, Feldman N, Hoffman A, and Glezerman M (2008) Determination of metformin transfer across the human placenta using a dually perfused ex vivo placental cotyledon model. *Eur J Obstet Gynecol Reprod Biol* **136**:29–33.

Kovo M, Kogman N, Ovadia O, Nakash I, Golan A, and Hoffman A (2008) Carrier-mediated transport of metformin across the human placenta determined by using the ex vivo perfusion of the placental cotyledon model. *Prenat Diagn* **28**:544–548.

Lee N, Duan H, Hebert MF, Liang CJ, Rice KM, and Wang J (2014) Taste of a Pill: ORGANIC CATION TRANSPORTER-3 (OCT3) MEDIATES METFORMIN ACCUMULATION AND SECRETION IN SALIVARY GLANDS. *J Biol Chem* **289**:27055–27064.

Lee N, Hebert MF, Prasad B, Easterling TR, Kelly EJ, Unadkat JD, and Wang J (2013) Effect of gestational age on mRNA and protein expression of polyspecific organic cation transporters during pregnancy. *Drug Metab Dispos* **41**:2225–2232.

**MOL #112482**

- Mager H, and Göller G (1998) Resampling methods in sparse sampling situations in preclinical pharmacokinetic studies. *J Pharm Sci* **87**:372–378.
- Masuda S, Terada T, Yonezawa A, Tanihara Y, Kishimoto K, Katsura T, Ogawa O, and Inui K (2006) Identification and functional characterization of a new human kidney-specific H<sup>+</sup>/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. *J Am Soc Nephrol* **17**:2127–2135.
- Morrissey KM, Stocker SL, Wittwer MB, Xu L, and Giacomini KM (2013) Renal transporters in drug development. *Annu Rev Pharmacol Toxicol* **53**:503–29.
- Otsuka M, Matsumoto T, Morimoto R, Arioka S, Omote H, and Moriyama Y (2005) A human transporter protein that mediates the final excretion step for toxic organic cations. *Proc Natl Acad Sci U S A* **102**:17923–17928.
- Ryu RJ, Hays KE, and Hebert MF (2014) Gestational diabetes mellitus management with oral hypoglycemic agents. *Semin Perinatol* **38**:508–515, Elsevier.
- Sata R, Ohtani H, Tsujimoto M, Murakami H, Koyabu N, Nakamura T, Uchiumi T, Kuwano M, Nagata H, Tsukimori K, Nakano H, and Sawada Y (2005) Functional analysis of organic cation transporter 3 expressed in human placenta. *J Pharmacol Exp Ther* **315**:888–895.
- Scheen AJ (1996) Clinical pharmacokinetics of metformin. *Clin Pharmacokinet* **30**:359–371.
- Shirasaka Y, Lee N, Zha W, Wagner D, and Wang J (2016) Involvement of Organic Cation Transporter 3 (Oct3/Slc22a3) in the Bioavailability and Pharmacokinetics of Antidiabetic Metformin in Mice. *Drug Metab Pharmacokinet* **3**:385–388, Elsevier Ltd.
- Simmons D (2011) Diabetes and obesity in pregnancy. *Best Pract Res Clin Obstet Gynaecol*

**MOL #112482**

**25:25–36**, Elsevier Ltd.

- Tanihara Y, Masuda S, Sato T, Katsura T, Ogawa O, and Inui KI (2007) Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H<sup>+</sup>-organic cation antiporters. *Biochem Pharmacol* **74**:359–371.
- Tucker GT, Casey C, Phillips PJ, Connor H, Ward JD, and Woods HF (1981) Metformin kinetics in healthy subjects and in patients with diabetes mellitus. *Br J Clin Pharmacol* **12**:235–246.
- Vähäkangas K, and Myllynen P (2009) Drug transporters in the human blood-placental barrier. *Br J Pharmacol* **158**:665–678.
- Vanky E, Zahlse K, Spigset O, and Carlsen SM (2005) Placental passage of metformin in women with polycystic ovary syndrome. *Fertil Steril* **83**:1575–1578.
- Verhaagh S, Barlow DP, and Zwart R (2001) The extraneuronal monoamine transporter Slc22a3/Orc13 co-localizes with the Maa metabolizing enzyme in mouse placenta. *Mech Dev* **100**:127–130.
- Wagner DJ, Hu T, Wang J, Wagner Tao Hu Joanne Wang DJ, David WJ, Tao H, and Joanne W (2016) Polyspecific organic cation transporters and their impact on drug intracellular levels and pharmacodynamics. *Pharmacol Res* **111**:237–246, Elsevier Ltd.
- Wagner DJ, Sager JE, Duan H, Isoherranen N, and Wang J (2017) Interaction and Transport of Methamphetamine and its Primary Metabolites by Organic Cation and Multidrug and Toxin Extrusion Transporters. *Drug Metab Dispos* **45**:770–778.
- Wensel TM (2009) Role of metformin in the treatment of gestational diabetes. *Ann Pharmacother* **43**:939–43.



**MOL #112482**

Westfall PH, and Young SS (1993) *Resampling-based multiple testing: Examples and methods for p-value adjustment*, John Wiley & Sons.

Wu X, Huang W, Ganapathy ME, Wang H, Kekuda R, Conway SJ, Leibach FH, and Ganapathy V (2000) Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney. *Am J Physiol Ren Physiol* **279**:F449-58.

Zhou M, Xia L, and Wang J (2007) Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine. *Drug Metab Dispos* **35**:1956–1962.

Zhu HJ, Appel DI, Gründemann D, and Markowitz JS (2010) Interaction of organic cation transporter 3 (SLC22A3) and amphetamine. *J Neurochem* **114**:142–149.

Zwart R, Verhaagh S, Buitelaar M, Barlow DP, and Popp-snijders C (2001) Impaired Activity of the Extraneuronal Monoamine Transporter System Known as Uptake-2 in Orct3 / Slc22a3-Deficient Mice Impaired Activity of the Extraneuronal Monoamine Transporter System Known as Uptake-2 in Orct3 / Slc22a3- Deficient Mice. *Mol Cell Biol* **21**:4188–4196.

**MOL #112482**

**FOOTNOTES**

This work was supported by National Institutes of Health [Grants U10HD047892, R01GM066233, T32GM007750].

**MOL #112482**

**FIGURE LEGENDS**

**Figure 1. Localization of OCT3 in human term placenta.** Human term placenta sections were co-labeled with antibodies for OCT3 (B, F, and J; *green*) and various membrane markers (C, CD31-PECAM1; G, laminin; K, the transferrin receptor; *red*). The nuclei were shown in blue (A, E, and I). Merged images are shown in D, H, and L. Arrow indicates representative staining of fetal capillaries (D) and basal membrane of trophoblasts (H).

**Figure 2. Expression of various organic cation transporters in the placentas of *Oct3*<sup>+/+</sup> and *Oct3*<sup>-/-</sup> mice.** Transcript of various organic cation and monoamine transporters in *Oct3*<sup>+/+</sup> (n=3) and *Oct3*<sup>-/-</sup> (n=3) mouse placentas at gd 19 was determined by real-time PCR.

**Figure 3. Maternal plasma metformin concentration-time profile in pregnant *Oct3*<sup>+/+</sup> (□) and *Oct3*<sup>-/-</sup> mice (■).** Pregnant (gd 19) *Oct3*<sup>+/+</sup> (□) and *Oct3*<sup>-/-</sup> (■) mice were given a dose (15 mg/kg) containing 0.2 mCi/kg of [<sup>14</sup>C]metformin by oral gavage. At various time points (0–480 min) after drug administration, animals were sacrificed and blood, tissues, and fetuses were collected. Metformin concentrations in maternal plasma were measured by liquid scintillation counting. Data represent mean ± 1.96 SE (n=3-5 mice/time point). Inset depicts the same data on a semi-logarithmic scale.

**Figure 4. Fetal metformin concentration-time profile in *Oct3*<sup>+/+</sup> and *Oct3*<sup>-/-</sup> mice following oral administration.** Pregnant (gd 19) *Oct3*<sup>+/+</sup> (□) and *Oct3*<sup>-/-</sup> (■) mice were given a dose (15 mg/kg) containing 0.2 mCi/kg of [<sup>14</sup>C]metformin by oral gavage. At various time points (0–480

## MOL #112482

min) after drug administration, animals were sacrificed and blood, tissues, and fetuses were collected. Metformin concentrations in fetus homogenates were determined by liquid scintillation counting. Data represent mean  $\pm$  1.96 SE (n=3-5 mice/time point).

### **Figure 5. Metformin AUC<sub>0-480</sub> in various tissues in pregnant *Oct3*<sup>+/+</sup> (□) and *Oct3*<sup>-/-</sup> mice (■).**

Pregnant (gd 19) *Oct3*<sup>+/+</sup> (□) and *Oct3*<sup>-/-</sup> (■) mice were given a 15 mg/kg metformin dose containing 0.2 mCi/kg of [<sup>14</sup>C]metformin by oral gavage. At various time points (0–480 min) after drug administration, animals were sacrificed and blood, tissues, and fetuses were collected. Metformin concentrations in various maternal tissues were determined and AUC<sub>0-480</sub> was calculated as described under Materials and Methods. Data represent mean  $\pm$  95% confidence interval. Two-sided *P* values were calculated using the permutation test as described under Materials and Methods (\**P*<0.05).

### **Figure 6. A proposed model for organic cation transport at the human placenta barrier.**

Organic cations, such as metformin, in the maternal circulation are first transported into the syncytiotrophoblast cells by NET, SERT, or OCTN2 at the apical membrane. Organic cations are then effluxed down their electrochemical gradient into the fetal side by OCT3 at the basal membrane. Larger and more lipophilic cations can be actively pumped back to the maternal circulation by P-gp and/or BCRP located at the apical membrane. NET, norepinephrine transporter; SERT, serotonin transporter; OCTN2, organic cation transporter novel type 2; P-gp, P-glycoprotein; BCRP, breast cancer resistance protein. This model is based on data in the present study and references (Ganapathy *et al.*, 2000; Vähäkangas and Myllynen, 2009).

# MOL #112482

## TABLES

**Table 1. Metformin pharmacokinetic parameters from pregnant *Oct3<sup>+/+</sup>* and *Oct3<sup>-/-</sup>* mice.**

Data are presented as mean  $\pm$  SE ( $C_{\max}$ ) or with 95% confidence intervals in parentheses.

	<i>Oct3<sup>+/+</sup></i>	<i>Oct3<sup>-/-</sup></i>
$C_{\max}$ ( $\mu\text{g/ml}$ )	$3.31 \pm 0.45$	$4.17 \pm 0.37$
$\text{AUC}_{0-480\text{min}}$ ( $\mu\text{g/ml} \cdot \text{min}$ )	609 (564, 698)	513* (452, 569)
$\text{AUC}_{0-\infty}$ ( $\mu\text{g/ml} \cdot \text{min}$ )	661 (616, 753)	556 (494, 615)
$\text{CL/F}$ ( $\text{ml/min/kg}$ )	24.6 (21.5, 26.6)	29.3 (26.4, 33.2)
$t_{1/2, \beta}$ (min)	119 (107, 195)	154 (99.2, 234)
$V_{\beta}$ (L/kg)	4.21 (3.60, 7.11)	6.51 (4.23, 10.3)

\* significantly different from *Oct3<sup>+/+</sup>* ( $P < 0.05$ )

**MOL #112482**

**Table 2. Fetal metformin AUC and AUC ratios in *Oct3<sup>+/+</sup>* and *Oct3<sup>-/-</sup>* pregnant mice.** Data are presented as mean with 95 % confidence intervals in parentheses.

	<i>Oct3<sup>+/+</sup></i>	<i>Oct3<sup>-/-</sup></i>	% change
AUC <sub>fetal, 0-480 min</sub> (µg/g*min)	127 (82.6, 146)	77.2* (66.9, 87.4)	39 %
AUC <sub>0-480</sub> Fetal-to-Maternal Ratio	0.21 (0.14, 0.25)	0.15* (0.13, 0.18)	29 %
AUC <sub>fetal, 0-∞</sub> (µg/g*min)	181 (136, 204)	95.7* (86.2, 104)	47 %
AUC <sub>0-∞</sub> Fetal-to-Maternal Ratio	0.27 (0.20, 0.32)	0.17* (0.15, 0.20)	44 %

\* significantly different from *Oct3<sup>+/+</sup>* (P < 0.05)